E.R. FDA Thursday, August 13, 2026 0.00 Neutral

FDA Approves ZENBEXUS — E.R. Squibb & Sons, L.L.C.

E.R. Squibb & Sons, L.L.C. received FDA approval for Iberdomide Hydrochloride, a novel oral lenalidomide analog, suggesting a potential for significant expansion of Squibb's market share in the liquid steroids market for multiple myeloma, contingent upon addressing potential safety concerns preceding the 2026 launch.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed